5-Amino-1methylquinolinium iodide
5-Amino-1-methylquinolin-1-ium iodide
CAS: 42464-96-0
Molecular Formula: C10H11IN2
5-Amino-1methylquinolinium iodide - Names and Identifiers
5-Amino-1methylquinolinium iodide - Physico-chemical Properties
| Molecular Formula | C10H11IN2 |
| Melting Point | 213-214 °C |
| Storage Condition | 2-8°C，避光，惰性气体保存 |
| MDL | MFCD22125886 |
| In vitro study | NNMTi (10-30 µM; 96 hours) produces a concentration-related increase in myoblast differentiation on C2C12 myoblast differentiation. 30 µM NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differentiation compared to untreated differentiating myoblasts (12% MHC-positive myotube nuclei). |
| In vivo study | NNMTi (subcutaneous (SC) injection; 5 mg/kg and 10 mg/kg; 2 weeks (1 week pre-injury and 1 week post-injury)) has an effect on muscle regeneration after injury, it results in 60% and 75% higher incidence of proliferating/active muSCs at 5 mg/kg and 10 mg/kg, respectively. The relative numbers of fibers with an EdU + myonucleus increased 40% and 48% with NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively. The odds ratio of fused myonuclei for control are 0.58 and 0.53 times the odds at the low and high NNMTi dose, respectively.NNMTi (subcutaneous injection; 10 mg/kg; 1 week) produces no systemic toxicity in mice, the levels of the glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated samples show no difference in mice. 1-week post-injury daily repeat-dosing of NNMTi is well tolerated with no untoward systemic toxicity or behavioral implications in aged mice. |
5-Amino-1methylquinolinium iodide - Reference Information
| biological activity | NNMTi is a potent nicotinamide N-methyltransferase (NNMT) the inhibitor (IC50=1.2 μm) can selectively bind to NNMT substrate binding site residues. NNMTi can promote the differentiation of myoblasts in vitro and enhance the fusion and regeneration ability of muscle stem cells in aged mice. |
| in vitro study | NNMTi (10-30 µm; 96 hours) products a concentration-related increase in myoblast difference on C2C12 myoblast difference. 30 µm NNMTi results in 18% MHC-positive myotube nuclei, representing a 45% increase in the extent of myoblast differential comparison to unmanaged differentiated mylatics (12% MHC-positive myoteube nuclei). |
| in vivo study | NNMTi (subcoutane (SC) injection; 5 mg/kg and 10 mg/kg; 2 weeks (1 week pre-injury and 1 week post-injury)) has an effect on muscle regeneration after injury, it results in 60% and 75% higher incidence of propagation/active muSCs at 5 mg/kg and 10 mg/kg, respectively. The relative numbers of fibers with an EdU + myonucleus increased 40% and 48% with NNMTi treatment at 5 mg/kg and 10 mg/kg, respectively. The odds ratio of fused myonuclei for control are 0.58 and 0.53 times the odds at the low and high NNMTi dose, respectively.NNMTi (subcutaneous injection; 10 mg/kg; 1 week) produces no systemic toxicity in mice, the levels of the glucose, cholesterol, plasma proteins, and electrolytes between control and NNMTi-treated samples show no difference in mice. 1-week post-injury daily repeat-dosing of NNMTi is well tolerated with no untoward systemic toxicity or behavioral implications in aged mice. |
Last Update：2024-04-09 21:01:54
Supplier List
Multiple SpecificationsSpot supply
Product Name: NNMTi Visit Supplier Webpage Request for quotationCAS: 42464-96-0
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple SpecificationsSpot supply
Product Name: NNMTi Visit Supplier Webpage Request for quotationCAS: 42464-96-0
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
View History